This consortium establishes a national academic infrastructure called NL-OPENSCREEN open to the Dutch life science community. Through NL-OPENSCREEN we will make small-molecule libraries and screening facilities available for high throughput and cell based testing against bio-molecular targets of scientific interest. Optimization programs will be provided, in which hit-structures are developed by chemical modification. This provides new and enabling research tools for fundamental biological and biomedical studies, as well as for further development into drug candidates.
NL-OPENSCREEN will assist users with the translation of bench-top assays into assay suitable for high-throughput or phenotypic screening.
Computational methods are routinely used in drug discovery and lead optimization projects. Within NL-OPENSCREEN ample expertise is available in the application of computational chemical biology (‘big data approaches’) and cheminformatics.
NL-OPENSCREEN has assembled ample expertise to add precise pharmacological texture to the screening results, by integrating ligand engagement / target binding kinetics into the various screening protocols.
Pivot Park Screening Centre accelerates drug discovery by using their long expertise on (u)HTS and their state-of-the-art robotic equipment to run screens in 384 or 1536-well format on a high quality compound library.
NL-OPENSCREEN will assemble high-quality targeted/focused compound libraries aimed at specific target protein families that will provide higher success rates.
Screen the cellular phenotypes of compound libraries in multiple dimensions.
Activity-based proteome profiling (ABPP) is an attractive and powerful chemical biological technique that accelerates most stages of the drug discovery process.
NL-OPENSCREEN is an integral part of the pan-European EU-OPENSCREEN network.